Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Key Highlights
- ➤Stryker received FDA 510(k) clearance for Sonopet 3 ultrasonic tissue-removal platform
- ➤Sonopet 3 adds RISE and Pulse Control technologies for integrated surgical workflows
- ➤First clinical cases begin in October; full commercial launch expected later this fall
Expert Statements
Mitch Foley, Vice president and general manager of Stryker's Neurosurgical business
“At Stryker, innovation begins with listening to our customers”
Mitch Foley, Vice president and general manager of Stryker's Neurosurgical business
“Every major advancement in Sonopet 3 can be attributed to surgeon feedback, and together we're elevating the standard in neurosurgery. They told us they wanted more power, improved ergonomics and enhanced integration, helping them perform with confidence in demanding surgical environments.”
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal PR Newswire
* Stryker has received FDA 510(k) clearance for Sonopet® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. * Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility. * Customers gain access to advanced technologies including RISE and Pulse Control, supporting streamlined workflows and integration across surgical settings. PORTAGE, Mich., Oct. 14, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that Sonopet 3, its latest ultrasonic bone and soft tissue removal platform, has received 510(k) clearance from the U.S. Food and Drug Administration.
Get started
Create a free account to read the full story.